Y Intercept Hong Kong Ltd Takes Position in Gilead Sciences, Inc. $GILD

Y Intercept Hong Kong Ltd purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 13,131 shares of the biopharmaceutical company’s stock, valued at approximately $1,458,000.

Several other large investors also recently added to or reduced their stakes in GILD. GoalVest Advisory LLC raised its holdings in shares of Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares in the last quarter. Corundum Trust Company INC bought a new position in shares of Gilead Sciences in the third quarter worth approximately $26,000. Harbor Asset Planning Inc. purchased a new stake in Gilead Sciences in the second quarter valued at approximately $27,000. Howard Hughes Medical Institute purchased a new stake in Gilead Sciences in the second quarter valued at approximately $30,000. Finally, Putney Financial Group LLC lifted its position in Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $125.08, for a total value of $625,400.00. Following the sale, the director owned 8,920 shares of the company’s stock, valued at $1,115,713.60. This trade represents a 35.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Deborah H. Telman sold 53,646 shares of the business’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total transaction of $6,590,411.10. Following the completion of the transaction, the executive vice president owned 43,676 shares in the company, valued at $5,365,596.60. The trade was a 55.12% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 257,397 shares of company stock valued at $33,385,512 over the last quarter. Company insiders own 0.27% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on GILD. Daiwa Capital Markets raised their price objective on shares of Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research report on Thursday, November 13th. Scotiabank initiated coverage on Gilead Sciences in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 target price on the stock. Wells Fargo & Company raised their price target on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research report on Wednesday, December 10th. UBS Group lifted their price target on Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Finally, The Goldman Sachs Group increased their price objective on Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a research report on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $136.36.

Gilead Sciences Price Performance

GILD opened at $141.95 on Friday. The stock’s 50 day simple moving average is $125.36 and its 200 day simple moving average is $119.59. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $142.20. The firm has a market cap of $176.11 billion, a price-to-earnings ratio of 22.01, a PEG ratio of 0.73 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.16 by $0.31. The firm had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business’s revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.02 earnings per share. As a group, analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Multiple sell‑side firms raised targets and reiterated bullish ratings (Wolfe Research to $155/outperform; TD Cowen to $145/buy), reinforcing buy-side momentum and implied upside from current levels. Read More. Read More.
• Positive Sentiment: Broader analyst upgrades/positive notes from Citi, Truist, BMO and UBS add to consensus bullishness, supporting demand and higher valuation multiples. Read More.
• Positive Sentiment: Clinical/regulatory wins for Trodelvy (added to NCCN guidelines; TNBC approval/win coverage) strengthen Gilead’s oncology growth story and revenue optionality beyond antivirals. Read More. Read More.
• Positive Sentiment: Coverage pieces noting that GILD has outperformed the market and is attracting analyst attention can draw momentum and ETF/quant flows into the stock. Read More.
• Neutral Sentiment: Notes on GILD’s presence in Nasdaq/healthcare ETF lineups and elevated investor attention increase volume and liquidity but are not clear directional catalysts by themselves. Read More.
• Negative Sentiment: Insider selling: CEO Daniel Patrick O’Day sold 10,000 shares (~$1.4M) at ~$139.89 (filed on Form 4). While modest relative to his remaining holding and potentially routine, insider sales can be interpreted negatively by some investors. Read More.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.